The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network by Harrold, Leslie R. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Faculty Publications 
2014-11-21 
The rheumatoid arthritis treat-to-target trial: a cluster randomized 
trial within the Corrona rheumatology network 
Leslie R. Harrold 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/faculty_pubs 
 Part of the Health Services Research Commons, Immune System Diseases Commons, 
Musculoskeletal Diseases Commons, and the Rheumatology Commons 
Repository Citation 
Harrold LR, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, 
Kremer JM. (2014). The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the 
Corrona rheumatology network. University of Massachusetts Medical School Faculty Publications. 
https://doi.org/10.1186/1471-2474-15-389. Retrieved from https://escholarship.umassmed.edu/
faculty_pubs/644 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For 
more information, please contact Lisa.Palmer@umassmed.edu. 
STUDY PROTOCOL Open Access
The rheumatoid arthritis treat-to-target trial: a
cluster randomized trial within the Corrona
rheumatology network
Leslie R Harrold1*, George W Reed1, J Timothy Harrington2, Christine J Barr3, Katherine C Saunders3, Allan Gibofsky4,
Jeffrey D Greenberg5, Ani John6, Jenny Devenport6 and Joel M Kremer7
Abstract
Background: The treat-to-target (T2T) approach to the care of patients with rheumatoid arthritis involves using
validated metrics to measure disease activity, frequent follow-up visits for patients with moderate to high disease
activity, and escalation of therapy when patients have inadequate therapeutic response as assessed by standard
disease activity scores. The study described is a newly launched cluster-randomized behavioral intervention to assess
the feasibility and effectiveness of the T2T approach in US rheumatology practices. It is designed to identify patient and
provider barriers to implementing T2T management. This initial paper focuses on the novel study design and methods
created to provide these insights.
Methods/Design: This trial cluster-randomizes rheumatology practices from the existing Corrona network of private
and academic sites rather than patients within sites or individual investigators to provide either T2T or usual care (UC)
for qualified patients who meet the 2010 revised American College of Rheumatology criteria for the diagnosis of
rheumatoid arthritis and have moderate to high disease activity. Specific medication choices are left to the investigator
and patient, rather than being specified in the protocol. Enrollment is expected to be completed by the end of 2013,
with 30 practices randomized and enrolling a minimum of 530 patients. During the 12-month follow-up, visits are
mandated as frequently as monthly in patients with active disease in the T2T group and every 3 months for the UC
group. Safety data are collected at each visit. The coprimary endpoints include a comparison of the proportion of
patients achieving low disease activity in the T2T and UC groups and assessment of the feasibility of implementing T2T
in rheumatology practices, specifically assessment of the rates of treatment acceleration, frequency of visits, time to
next visit conditional on disease activity, and probability of acceleration conditional on disease activity in the 2 groups.
Discussion: This cluster-randomized behavioral intervention study will provide valuable insights on the outcomes and
feasibility of employing a T2T treatment approach in clinical practice in the United States.
Trial registration: NCT01407419
Keywords: Treat to target, Rheumatoid arthritis, Corrona, Usual care
Background
An estimated 1.3 million people in the United States are
affected by rheumatoid arthritis (RA), a chronic, pro-
gressive, inflammatory disease that causes pain, joint
damage, and disability [1]. It is estimated that 20% to
30% of patients with early RA become permanently
disabled during the first 2 to 3 years of the disease [2].
The ultimate goal of treatment is to achieve remission of
active inflammation, given that a substantial proportion
of patients show radiographic progression even while in
a state of low disease activity (LDA) [3,4]. Remission is now
possible in many patients with RA treated early and aggres-
sively with an increasing array of effective medications.
Treatment generally starts with traditional nonbiologic
disease-modifying antirheumatic drugs (DMARDs), and if
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remission is not achieved, nonbiologic DMARDs can be
combined and/or biologic DMARDs can be initiated [5].
There is a growing consensus that rheumatologists
should measure patient disease activity using validated
composite clinical measures and then accelerate treat-
ment until the disease is in remission, an approach
referred to as treat-to-target (T2T) management [6].
Studies comparing T2T management with usual care
(UC) have clearly shown T2T to be superior. The Tight
Control of Rheumatoid Arthritis (TICORA) trial demon-
strated an advantage of T2T care using only standard
DMARDs with mandatory acceleration every 3 months
in selected patients with early RA [7]. Findings from the
TICORA trial have since been confirmed in multiple
other studies of tight control treatment strategies, includ-
ing data from the Dutch Rheumatoid Arthritis Monitoring
registry and the Computer Assisted Management in
Early Rheumatoid Arthritis (CAMERA) trial [8,9]. These
trials were performed in Europe, where access to biologic
agents is significantly restricted compared with the United
States [10].
The feasibility and advantages of T2T management
relative to UC still need to be verified in US rheumatology
practices, in more representative US RA populations, and
in the absence of specific protocols that rigidly define
treatment choices, which may not be practical in routine
care. For these reasons, a US-based, independent observa-
tional registry (Corrona, LLC) has designed and launched
a behavioral intervention clinical trial, cluster-randomized
by practice sites into T2T and UC management, for
patients with moderate to high RA disease activity at
enrollment. This initial paper focuses on the novel
study design and methods created to evaluate these
research questions and the rationale underlying these
methodological decisions. The feasibility assessments of
visits and treatment accelerations mandated by this
protocol, and the barriers to implementing the treatment
protocols, are critical to understanding whether prac-
ticing US rheumatologists will be able to successfully
and routinely apply T2T management.
The Corrona T2T trial is enrolling patients with mod-
erate to high disease activity as measured by the Clinical
Disease Activity Index (CDAI), an instrument commonly
used in the US and recommended by the American College
of Rheumatology for evaluation of disease activity [11]. The
trial mandates assessment of disease activity with monthly
visits in the T2T intervention group and up to monthly
treatment acceleration until disease control is achieved.
The Corrona study does not recommend any specific
medication treatments—rather a variety of traditional
and biologic DMARD options may be employed at the
discretion of the treating rheumatologist investigator
(Table 1). The UC sites are required only to provide a
Corrona RA report every 3 months for visits that took
place for their enrolled patients, and treatments and visit
schedule for a patient are determined at the discretion of
the individual rheumatologist.
Corrona, LLC was founded in 2001 and currently
includes ≥160 rheumatology practices (80% private
practice) and ≥600 rheumatologists across 40 states in
the United States. The registry collects longitudinal “real-
world” data from patients and their treating rheumatology
providers during routine clinical visits. As of March 3rd,
2014, data have been collected on more than 39,956
patients with rheumatologist-diagnosed RA. Patient- and
provider-reported data collected at each Corrona registry
visit include RA disease severity and activity; present and
past RA treatments with doses, comorbidities, adverse
events, and selected laboratory and imaging results; socio-
demographic information; and a range of patient-reported
outcomes.
Methods/Design
Objective and design
The T2T study is a 12-month trial with cluster random-
ization. The protocol mandates increased visit frequency
and treatment acceleration in patients with active disease
at T2T sites but not at UC sites, where visits and collec-
tion of routine Corrona data are required every 3 months
(Figure 1). Cluster-randomized trials are characterized by
randomization at the level of the cluster or group—in the
case of this study, the cluster was clinic sites [13-15]. All
individuals in the cluster were assigned to the same study
arm. The approach was used because it would be difficult,
if not impossible, for a doctor to treat patients differ-
ently based on treatment assignment—i.e., treating some
patients to target while giving “usual care” to others.
The coprimary objectives of the study are to (1) examine
achievement of LDA in each site’s enrolled population
based on the CDAI at 12 months (CDAI ≤10) and (2)
assess the feasibility of a T2T approach by comparing rates
of treatment acceleration, visit frequency conditional on
disease activity, and probability of treatment acceleration
conditional on disease activity in the T2T group compared
Table 1 Comparison of features of TICORA, BeSt, and
Corrona T2T with EULAR recommendations [12]
TICORA BeSt Corrona T2T EULAR
Mandated acceleration Yes Yes Yes Yes
Biologics accessible No Yes Yes Yes
Predefined acceleration order
of therapeutic options
Yes Yes No No
Biologic prevalence in
RA population ≥20%
No No Yes No
Unique cost-effectiveness climate Yes Yes Yes Yes
BeSt: Behandel Strategieen (study); EULAR, European League Against
Rheumatism; RA, rheumatoid arthritis; T2T, treat to target; TICORA: Tight
Control of Rheumatoid Arthritis.
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with the UC group at 12 months. Secondary objectives
are to (1) assess mediators of differences in LDA rates
between groups, including specific medication uses and
frequency of medication acceleration; (2) examine whether
the impact of physician acceleration of medication use
in those patients with active disease in both the T2T
and UC groups is associated with achieving LDA; (3)
determine the proportion of patients who achieve LDA
at 6 months; (4) compare the performance of the 28-joint
disease activity score via erythrocyte sedimentation rate
(DAS28-ESR) and Routine Assessment of Patient Index
Data 3 (RAPID3) at 6 and 12 months; (5) determine the
frequency of ineligibility for treatment acceleration; (6)
determine the rates of drug toxicities over 12 months;
and (7) compare the rates of adverse events of special
interest, termed targeted adverse events.
Study site recruitment
For this study, we approached rheumatology practices
that currently participate in Corrona as well as other
practices not previously affiliated with Corrona. Sites
already participating in the Corrona Effectiveness Regis-
try to Study Therapies for Arthritis and Inflammatory
Conditions (CERTAIN) comparative effectiveness trial
were excluded so as not to interfere with the primary
endpoint analyses in individual studies as the recruit-
ment criteria in these studies are quite similar [16]. Sites
that expressed interest in the trial were invited to review
the protocol and complete a feasibility assessment after
signing a nondisclosure agreement. Feasibility data were
reviewed by the project team, and sites were formally
invited to participate if they had the interest and cap-
acity to meet the expectations for the trial. Some of the
invited sites declined to participate in the study, and the
reasons provided were tracked and included lack of
adequate staff resources, current project load, institutional
review board (IRB) concerns (primarily at academic sites),
and other priorities of the sites (for example, transitioning
to electronic medical records).
Sites were stratified by size and were asked to assess the
number of participants they would enroll. Using a cutoff
of 34 based on sample size and power calculations, the
sites were classified as large or small for the purpose of
randomization. Sites were then randomized in a 1:1 ratio
to either the T2T or UC cluster after obtaining IRB
approval. Approvals for the study were obtained from local
institutional review boards of participating academic sites
and a central institutional review board (New England
IRB) for private practice sites. Site allocation remained
sealed until after the participating physicians obtained
IRB approval. Then sites received training materials and
initiation training specific to their assignment. Patient
recruitment began in July 2011.
Figure 1 The flow diagram of the treat-to-target study. CDAI,
Clinical Disease Activity Index; EOS, end of study; T2T, treat to target;
UC, usual care.
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Physician and staff training
Investigators and staff at all participating sites received
training by phone on the T2T trial protocol. The manual
of procedures was reviewed with the principal investigator
and site staff during this 30- to 60-minute training call,
and questions about the protocol and trial activities were
answered. T2T and UC sites received separate instructions
specific to their visit and treatment acceleration expecta-
tions. In addition, training was supplemented as needed via
e-mail, newsletter reminders, site feedback, and telephone
discussions. Retraining was completed on an as-needed
basis for sites that experienced ongoing challenges in
adhering to the protocol and/or completing required
clinical questionnaires. In addition to trial-specific train-
ing, investigators and site staff were documented to be
up-to-date on Good Clinical Practices (GCP) training
for research involving human subjects.
Protocol-defined inclusion and exclusion criteria were
carefully reviewed with the physician investigators in
both arms during the site-training teleconference before
site activation to ensure that the target population was
clearly defined. Investigators were also encouraged to call
with any eligibility questions during the course of the trial.
Misconceptions were addressed as detected, and feedback
regarding challenges was regularly encouraged. Specific
recruitment activities and levels at individual sites may
vary based on available resources, provider schedules,
workloads, and other considerations. Eligibility training
and support was consistent across treatment arms.
Patient recruitment
Patients with RA and active disease (CDAI >10) are
invited to participate by their treating rheumatologists.
Specific inclusion criteria are outpatients aged ≥18 years
with RA according to the America College of Rheuma-
tology (ACR) criteria, moderate to high disease activity
based on the CDAI, and patient agreement with the
schedule of study visits and provision of informed con-
sent. Additionally, patients need to be deemed clinically
and medically appropriate for treatment acceleration by
the rheumatologist-investigator and willing to have their
therapy escalated as appropriate. Patients were not ex-
cluded based on RA disease duration or prior medication
use to ensure a real-world sample of participants.
Exclusion criteria are current or planned pregnancy and/
or breastfeeding during the study period; planned surgery;
ACR functional class IV; prednisone daily doses >10 mg
within the prior 4 weeks; history of serious infection
(defined as follows: (1) 1 hospitalization or use of paren-
teral antibiotics within the past 6 months, (2) ≥2 hospitali-
zations or courses of parenteral antibiotics within the
past 12 months, (3) tuberculosis infection, (4) infection
with human immunodeficiency virus, (5) hepatitis B
virus infection, or (6) hepatitis C virus infection); serious
comorbidities; chronic pain syndrome that either con-
founds or makes difficult the assessment of RA disease
activity; and recent dose changes of traditional and
biologic DMARDs that, in the opinion of the treating
rheumatologist, have not had sufficient time to mean-
ingfully impact disease activity.
T2T intervention and UC sites
Patients enrolled in the T2T arm have mandated visits
and treatment acceleration dependent on patient disease
activity and physician discretion. As shown in Table 2,
monthly visits are mandated as long as the patient
continues to have a CDAI >10 (moderate to high disease
activity), and treatment acceleration is mandated at least
every 3 months until low disease activity is achieved or
until end of the study (can be as frequently as monthly).
Treatment acceleration is defined as a dosage increase in
nonbiologic or biologic DMARDs, the addition or switch-
ing of nonbiologic or biologic DMARDs, or changing
from oral to subcutaneous methotrexate administration.
For infliximab, this includes a decrease in the dosing inter-
val. In accordance with GCP, patients and investigators at
the T2T sites may decide not to accelerate treatment, even
if the CDAI criteria for acceleration are met, based on
Table 2 Schedule of visits and laboratory assessments over the study period
Procedure Baseline Monthly visits Month 3 Month 6 Month 9 Month 12/End of study
Informed consent for T2T study T2T, UC
Corrona patient and physician enrollment questionnaires T2T, UC
Corrona patient and physician follow-up questionnaires T2T T2T, UC T2T, UC T2T, UC T2T, UC
Baseline case report form T2T, UC
Study follow-up visit case report form T2T T2T, UC T2T, UC T2T, UC T2T, UC
T2T-arm–only questionnaire T2T T2T T2T T2T T2T T2T
Corrona participant exit form (specify T2T study) T2T, UC
Laboratory assessments
Erythrocyte sedimentation rate T2T, UC T2T, UC T2T, UC T2T, UC T2T, UC
T2T, treat to target; UC, usual care.
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clinical reasons and/or patient preferences, as noted previ-
ously. Reasons for not accelerating treatment are recorded
by the investigators. These include new or worsening
comorbid conditions, anticipated lag in response time for
recently initiated therapy, upcoming surgeries, pregnancy
and/or breastfeeding, elevated CDAI deemed by the treat-
ing rheumatologist to be unrelated to RA (eg, a chronic or
acute pain condition), and patient refusal.
Patients in the UC arm are required to return for visits
and complete Corrona reports every 3 months, but care
is otherwise left to the discretion of the investigators at
sites randomized to this arm. Patients at most sites are
paid a nominal amount for their participation to com-
pensate for the inconvenience of frequent visits and
cover the cost of gas, and these payments were approved
by the appropriate independent review boards.
Clinical assessment
At each visit, 3 composite disease activity scores are
collected, including CDAI, DAS28, and RAPID3. Erythro-
cyte sedimentation rate is determined locally every
3 months using the Westergren method. Frequencies
of visits to the site by patients in both groups will be
measured. All changes in nonsteroidal anti-inflammatory
drugs, glucocorticoids, nonbiologic DMARDs, and bio-
logics will be tracked throughout the course of the
study. Additionally, any serious adverse events will be
reported to Corrona within 48 hours, and the participating
providers will be asked to report these as necessary to
the US Food and Drug Administration and/or drug
manufacturer. Targeted adverse events include anaphylaxis,
cancers/malignancies, cardiovascular events (revasculariza-
tion procedure, ventricular arrhythmia, cardiac arrest,
myocardial infarction, acute coronary syndrome, unstable
angina, congestive heart failure, stroke, and transient
ischemic attack), gastrointestinal perforation, hospitaliza-
tions or biopsies for hepatic dysfunction, serious infection
(infections requiring hospitalizations or intravenous anti-
biotics), neurological events (hospitalization, progressive
multifocal leukoencephalopathy and other demyelinating
diseases), and serious spontaneous bleeding requiring
hospitalizations.
Analysis plans
Coprimary endpoints will assess the differences between
the randomized groups in physician behavior and patient
disease activity. Specifically, we will compare the rates
of physician visits (visits per patient-years of follow-up)
and rates of acceleration (accelerations per visits with
CDAI >10) between the T2T and UC sites to see if there
are differences in the care approaches between the two
treatment arms (e.g., visit frequency and tight control).
In addition, we will compare achievement of LDA at
12 months from baseline by an intent-to-treat analysis.
The unit of analysis for visit rates and LDA rates will be
patient-clustered within physician and within site (the
unit of randomization). Patients as well as physician
treatment patterns will differ by site, but these differences
should be balanced by site randomization. If large differ-
ences do exist in patient characteristics by arm even after
site randomization, adjustment for those characteristics
can be carried out. Random-effects regression models will
be used to assess and account for correlations due to clus-
tering. Assessment of differences in patient characteristics
across sites will be made because the randomization was
by site not by patient, and the comparison between ran-
domized arms will be adjusted for differences. For analysis
of acceleration, the unit of analysis will be a patient visit
(with CDAI >10), which adds the additional clustering of
visit within patient. Several secondary and exploratory
analyses are planned. These include using the above men-
tioned methodology to evaluate the differences in the two
treatment arms using the DAS28-ESR and the patient-
reported outcomes based on the RAPID3 [17]. In addition,
we will perform analyses that will focus on time to next
visit when a patient has moderate to severe disease activ-
ity, rates of targeted adverse events, and differences in
continual measures of disease activity. Specifically, rates of
drug toxicities over 12 months will be calculated based
on the reported number of toxicities per person-time of
follow up using a random-effects Poisson regression
model adjusting for the levels of clustering and potential
confounders. We will estimate and test differences in
continual measures of disease activity using random-
effects linear regression models adjusting for the levels
of clustering and compare mean changes in scores
between the T2T and UC groups.
Determination of sample size
A recruitment goal of 16 patients per site was determined
to provide maximum analytic power for analysis of out-
comes. Specifically, the choice of 15 sites per group with
16 patients per site was based on power estimates using
intraclass correlation (ICC) estimates and estimated LDA
rates observed in the Corrona registry, the possibility of
dropped sites, and some imbalance in patients per site.
The goal of recruiting 530 patients (265 per randomized
arm) assumed a 10% dropout rate during the course of
the study. With ICC =0.09 and the alternative hypothesis
of 40% LDA vs 60% LDA at 1-year follow-up in the 2 ran-
domized groups (control vs T2T), there is 80% power for
14 sites per group and 16 patients per site or 15 sites per
group and 14 patients per site. Choosing 15 sites per
group and 16 patients per site allowed for the possibility
of loss of a site per group and any minor loss of power
due to imbalance in patients per site—1% to 3%, with
moderate imbalance [18].
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Discussion
The T2T clinical trial is a newly launched cluster-
randomized behavioral intervention study examining
the outcomes and feasibility of a T2T treatment paradigm
in clinical practice in the United States. This includes
evaluating whether patients and providers are able to
adhere to a T2T protocol in terms of both visit frequency
and treatment acceleration in those with persistent active
disease. The established infrastructure of Corrona is
used for patient enrollment, physician participation,
and collection and storage of data. The commitment of
Corrona investigators and enrolled patients to providing
standardized, validated reports during routine visits is
leveraged to perform this T2T clinical trial in which visits
and laboratory evaluations are instead mandated at regular
but different intervals at the T2T and UC sites.
Protocol development for this trial was interesting in
several respects. Randomizing T2T and UC care by patients
or individual investigators within the same site was rejected
due to the likelihood of treatment protocol crossover. That
is, it would be very challenging for the investigators at a site
to treat the patients differently. Randomizing participating
sites was seen as critical to addressing this issue and
attempting to control for potential differences in disease
activity measurement and treatment acceleration from site
to site and potentially across investigators within sites.
Given this novel approach, the Corrona statistical group
was compelled to carefully consider optimal powering and
analytic approaches. Using a cluster randomization trial
design, the Corrona statistical group followed the method-
ologies described by Donner and Klar for power and
sample size estimates and the use of mixed-effects
models for analytic procedures [14]. The practical issues
of both patient and site dropout and patient sample
imbalance across sites were also addressed.
The major limitation of this trial may reside in the
investigators’ discretion regarding treatment acceleration
and treatments selected. UC investigators may elect to
accelerate care and prescribe biologic DMARDs frequently,
and T2T investigators may choose not to do so. In either
case, the differences in treatments and disease activity
measurements may be less than expected from historical
Corrona registry data.
In summary, the T2T study harnesses the expertise
and experience of Corrona’s scientific team and existing
network to evaluate whether T2T improves outcomes
without compromising safety and how to incorporate
T2T treatment into clinical practice. We look forward to
communicating the results of this novel trial.
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